Completed PHASE3 INTERVENTIONAL 2-arm NCT01033877

Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults

Immunogenicity and Safety of a Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to a Tetanus and Diphtheria (Td) Vaccine When Given as a Booster Vaccination to Adults

Sponsor: Statens Serum Institut

Conditions Healthy

Interventions Td vaccine SSI TdaP vaccine SSI

Updated 5 times since 2017 Last updated: Jan 18, 2013 Started: Jan 31, 2010 Primary completion: Aug 31, 2010 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01033877, this PHASE3 trial focuses on Healthy and remains completed. Sponsored by Statens Serum Institut, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Statens Serum Institut

Data source: Statens Serum Institut

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark
• Hoersholm, Denmark